Exploring generic drug use behavior the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution

Medical Care

Volumn 40, Issue 8, 2002, Pages 662-674

  Mott, David A ^a   Cline, Richard R ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; DATA BASE; DRUG INDUSTRY; DRUG UTILIZATION; FEMALE; HEALTH SERVICES RESEARCH; HUMAN; MALE; MEDICAL INFORMATION SYSTEM; MIDDLE AGED; PHARMACIST; PHARMACY; PRESCRIPTION; PROFESSIONAL STANDARD; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADULT; CLINICAL PHARMACY INFORMATION SYSTEMS; DATABASES; DRUG INDUSTRY; DRUG UTILIZATION; DRUGS, GENERIC; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MIDWESTERN UNITED STATES; PHARMACIES; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROFESSIONAL ROLE;

EID: 0036674814     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200208000-00006     Document Type: Article

References (33)

1. Kreling D, Mott D, Wiederholt J, et al. Prescription Drug Trends: A Chartbook Update. Menlo Park, CA: Kaiser Family Foundation; 2001.
2. The drug price competition and patent term restoration act of 1984. PL98-417:98 Stat 1984:1585.
3. Grabowski H, Vernon J. Substitution laws and innovation in the pharmaceutical industry. Law Contemp Prob 1979;43:43.
4. Neff A, Simpson T. Drug substitution rate advances: market measures. Drug Top 1992;17:16.
5. Vaczek D. Plans squeeze generic profitability. Am Drug 1995;212:40.
6. Kreling D, Mott D, Wiederholt J, et al. Prescription Drug Trends: A Chartbook. Menlo Park, CA: Kaiser Family Foundation; 2000.
7. Pauly M. Doctors and Their Workshops. Chicago, IL: Chicago University Press; 1980.
8. Blomqvist A. The doctor as double agent: information asymmetry, health insurance, and medical care J Health Econ 1991;10:411.
9. Caves R, Hurwitz M. Persuasion or Information? Promotion and the shares of brand name and generic pharmaceuticals. J Law Econ 1988;31:299.
10. Coscelli A. The importance of doctors' and patients' preferences in the prescription decision. J Indus Econ 2000;48:349.
11. Hellerstein J. The importance of the physician in the generic versus trade-name prescription decision. RAND J Econ 1998;29:108.
12. Lundin D. Moral hazard in physician prescription behavior. J Health Econ 2000;19:639.
13. Zweifel P, Breyer F. Health Economics. New York, NY: Oxford University Press; 1997.
14. Mott D, Kreling D. The association of insurance type with costs of dispensed drugs. Inquiry 1998;35:23-35.
15. Wolfgang A, Perri M. Older adults and generic drugs: an analysis of attitudes and intentions. J Pharm Market Manage 1991;5:97.
16. US Department of Health and Human Services. Prescription Drug Coverage, Spending, Utilization, and Prices. Washington, DC: US Department of Health and Human Services; 2000.
17. Poisal J, Chulis G. Medicare beneficiaries and drug coverage. Health Aff 2000;March/April:248.
18. Podulka M, Krautkramer K, Amerson D, et al. Consumers' attitudes toward generic drugs. J Pharm Market and Manage 1989;4(1):93.
19. Mott D, Kreling D. The influence of therapeutic category and insurance type on generic substitution of drug products. J Res Pharm Econ 1997;8(3):3.
20. Medical Economics Company. Red Book-96. Montvale, NJ: Medical Economics Company; 1995.
21. FOI Services. The NDA Book, Volume 2. Gaithersburg, MD: FOI Services; 1995.
22. Neuhaus J. Statistical methods for longitudinal and clustered designs with binary responses. Stat Meth Med Res 1992;1:249.
23. Schondelmeyer S, Seoane-Vasquez E. Pharmacists are working harder. Am Drug 1997;8:34.
24. Grom T. Generics: best years to come. Med Ad News 1999;10:1.
25. Reichert S, Simon T, Halm E. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Int Med 2000;160:2799.
26. Novartis Pharmaceuticals. Novartis Pharmacy Benefit Report: Facts and Figures 1999 Edition. East Hanover, NJ:Novartis Pharmaceuticals Corporation; 1999.
27. Mays G, Hurley R, Grossman J. Consumers face higher costs as health plans seek to control drug spending. Issue Brief Findings from HSC 2001;45:1-4.
28. Avorn J, Soumerai S. Improving drug therapy decisions through educational outreach: a randomized controlled trial of academically based detailing. N Engl J Med 1983;308:1457.
29. Anonymous. Generic: drug sampling program saves HMO nearly $200,000 in 9 months. Formulary 2000;35:82-83.
30. Hillman A, Pauly M, Escarce J, et al. Financial incentives and drug spending in managed care. Health Aff 1999;March/April:189.
31. Banahan B III, Kolassa E. A physician survey on generic drugs and substitution of critical dose medications. Arch Int Med 1997;157:2080-2088.
32. Aventis Pharmaceuticals. 2000 HMO-PPO/ Medicare-Medicaid Digest. Parsippany, NJ: Aventis Pharmaceuticals; 2000.
33. Adams P, Hendershot G, Marano M. Current estimates from the national health interview survey, 1996. Washington, DC:National Center for Health Statistics. Vital Health Stat 1999:10;200.